Expertise in
9
conditions

Batia R. Avni

Hadassah Ein Kerem
Jerusalem, JM, IL 
Expertise in
9
conditions
Hadassah Ein Kerem
Jerusalem, JM, IL 
OverviewLocationsClinical Research

Overview

Batia Avni practices in Jerusalem, Israel. Avni is highly rated in 9 conditions, according to our data. Their top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Congenital Aplastic Anemia, Bone Marrow Transplant, and Bone Graft.

Their clinical research consists of co-authoring 57 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Hadassah Ein Kerem
Jerusalem, JM, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: December 16, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
View 1 Less Clinical Trial

57 Total Publications

Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 09, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Avni's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile